Efficacy of Treatment with Irinotecan and Oxaliplatin Combination in FU-Resistant Metastatic Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|66|2|132-137

ISSN： 0030-2414

Source： Oncology, Vol.66, Iss.2, 2004-05, pp. : 132-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Treatment of Patients with Metastatic Colorectal Carcinoma

By  

Oncology Research and Treatment, Vol. 30, Iss. 4, 2007-03 ,pp. : 169-174

Karger

Access to resources Recommend Favorite

Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 11, 2014-10 ,pp. : 646-652

Karger

Access to resources Recommend Favorite

The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 29, Iss. 12, 2006-12 ,pp. : 563-567

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite